Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
IPO Year: 2020
Exchange: NASDAQ
Website: inventivapharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/21/2025 | $10.00 | Buy | TD Cowen |
| 11/12/2024 | $3.00 | Neutral | UBS |
| 10/27/2023 | $12.00 | Buy | Canaccord Genuity |
| 5/31/2023 | $11.00 | Buy | ROTH MKM |
| 5/19/2023 | Sell → Buy | Societe Generale | |
| 3/17/2023 | $27.00 | Buy | Stifel |
| 11/15/2022 | Buy → Sell | Societe Generale | |
| 11/22/2021 | $40.00 → $42.00 | Buy | HC Wainwright & Co. |
| 9/22/2021 | $38.00 → $40.00 | Buy | HC Wainwright & Co. |
6-K - Inventiva S.A. (0001756594) (Filer)
6-K - Inventiva S.A. (0001756594) (Filer)
6-K - Inventiva S.A. (0001756594) (Filer)
SCHEDULE 13G - Inventiva S.A. (0001756594) (Subject)
6-K - Inventiva S.A. (0001756594) (Filer)
6-K - Inventiva S.A. (0001756594) (Filer)
6-K - Inventiva S.A. (0001756594) (Filer)
SCHEDULE 13G - Inventiva S.A. (0001756594) (Subject)
SCHEDULE 13D/A - Inventiva S.A. (0001756594) (Subject)
6-K - Inventiva S.A. (0001756594) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
TD Cowen initiated coverage of Inventiva with a rating of Buy and set a new price target of $10.00
UBS initiated coverage of Inventiva with a rating of Neutral and set a new price target of $3.00
Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00
ROTH MKM initiated coverage of Inventiva with a rating of Buy and set a new price target of $11.00
Societe Generale upgraded Inventiva from Sell to Buy
Stifel initiated coverage of Inventiva with a rating of Buy and set a new price target of $27.00
Societe Generale downgraded Inventiva from Buy to Sell
HC Wainwright & Co. reiterated coverage of Inventiva with a rating of Buy and set a new price target of $42.00 from $40.00 previously
HC Wainwright & Co. reiterated coverage of Inventiva with a rating of Buy and set a new price target of $40.00 from $38.00 previously
Societe Generale resumed coverage of Inventiva with a rating of Sell
Fastest customizable press release news feed in the world
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David Nikodem, PhD, Vice President of US Operations will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. The conference is being held from August 12-14, 2025, at the InterContinental Hotel in Boston, Massachusetts. During the fireside chat, Drs. Campagna and Nikodem wil
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2025: Cash:
Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United States), July 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported certain preliminary financial results for the first half of 2025, including its cash, cash equivalents, and revenues. Preliminary Financial Results As of June 30, 2025, the Company's cash and cash equivalents amounted
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic
Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd ("CTTQ"), a subsidiary of Sino Biopharm. This milestone payment follows the successful settlement of the second tranche of €115.6 million1 in gross proceeds (net proceeds of €108.5 million) of the previously announced structured financing of up to €348 million2 (the "St
Analysis of liver sinusoidal endothelial cells ("LSEC") from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and a further increased capillarization in patients with MASH In addition, in the subgroup of patients without MASH, there was higher LSEC capillarization in patients with MASLD than those with normal histology LSEC capillarization observed in patients was strongly associated with liver fibrosis and to a lesser extent inflammationEnd of treatment biopsies from Phase 2b NATIVE showed improvement in LSEC capillarization in patients with MASH and treated with lanifibranor compared to placeboIn additio
Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company's Annual General Meeting. Mark Pruzanski, Chairman of Inventiva: "We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva's journey. Her exceptional track record in our industry speaks for itself and will be
Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the Company's Management will participate in two upcoming investor conferences in June 2025. Frédéric Cren, CEO and cofounder of Inventiva, will present a corporate overview during a fireside chat at the Jefferies Global Healthcare Conference which will take place in New York on June 4th at 10:30am ET. The fireside chat will be webcast live and will be access
Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues. Key Financial Results Cash, cash equivalents and deposits As of March 31, 2025, the Company's cash and cash equivalents amounted to €67.9 million, compared to €96.6 million as of December 31, 2024. The decrease of €28.7 million is
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the results of the votes of its Combined Shareholders' Meeting. The Combined Shareholders' Meeting was held on Thursday May 22, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (France), under the chairmanship of Mr. Frédéric Cren, Chief Executive Officer and cofounder of Inventiva. Mr. Frederic Cren proceeded to the usual formalities of the opening of the meetin
Live Leadership Updates
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic
Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company's Annual General Meeting. Mark Pruzanski, Chairman of Inventiva: "We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva's journey. Her exceptional track record in our industry speaks for itself and will be
Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024. Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica
Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva's Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomized in the NATiV3 study evaluating lanifibranor for the treatment of noncirrhotic MASH, with completion of enrollment projected in 1H 2025.Appointment to the Board of Directors of Mark Pruzanski, MD,
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne's appointment will be submitted to the shareholders for ratification at the next general shareholder meeting. Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva: "We are extre
Forbion Appoints Nanna Lüneborg as a General Partner - Brings extensive international investment and board experience in life sciences companies of all sizes including company creations, private venture deals and IPOs - Naarden, The Netherlands, 1 September 2021 – Forbion, a leading European life sciences venture capital firm, today announces the appointment of Nanna Lüneborg, PhD as a General Partner to work on the €360m Forbion Growth Opportunities Fund. Prior to joining Forbion, Nanna was a Partner at Novo Ventures and a key member of the European deal team focussing on late-stage biopharma investments across Europe. During her 10 years at Novo, Nanna was involved in numerous success
Daix (France), April 19, 2021 – Inventiva (NASDAQ:IVA) is pleased to announce the appointment of Martine Zimmermann to its Board of Directors as an independent director. Inventiva's Board of Directors appointed Martine Zimmerman to replace Nawal Ouzren, who resigned from the Board of Directors in order to focus on the growth of Sensorion. Martine Zimmerman's appointment will be submitted to the shareholders for ratification at the next general shareholders meeting. With over 25 years of global experience in the pharmaceutical industry, Martine Zimmermann has been the Senior Vice President and Head of Global Regulatory Affairs of Alexion Pharma International since June 2016. Throughout h
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil, MD, has been appointed Chair of the Board. Additionally, Nawal Ouzren has been appointed as a new Board member. “These changes in our Board leadership will help position Arena for the growth we anticipate and mark an important inflection point in our progress,” said Amit D. Munshi, President and CEO of Arena. “Garry Neil has served on the Board for the past four years, providing exceptional leadership for our scientific direction. As a physician with extensive industry experience, his insight into successfully translating scientific disco
This live feed shows all institutional transactions in real time.
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13G/A - Inventiva S.A. (0001756594) (Subject)
SC 13G/A - Inventiva S.A. (0001756594) (Subject)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13G - Inventiva S.A. (0001756594) (Subject)
SC 13G/A - Inventiva S.A. (0001756594) (Subject)
SC 13G/A - Inventiva S.A. (0001756594) (Subject)
Live finance-specific insights
Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi
Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder
Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.Blinded analyses of patients in NATiV3 suggest a positive evolution of key biomarkers comparable to the Phase IIb, NATIVE, study results and that weight gain plateaus and stabilizes starting at week 24 to 36.Last patient randomization is anticipated in the first half of 20
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit at €9.0 million2 as of December 31, 2023, compared to €86.7 million, €1.0 million, and €0.7 million respectively, as of December 31, 2022 In September 2023, Inventiva entered into an exclusive licensing agreement with Hepalys to develop and commercialize lanifibranor in Japan and South Korea In January 2024, Inventiva received the second tranche of €25 million under the EIB loan agreement following its August 2023 financing of €35.7 million in gross proceeds, the upfront payment of $10 mill
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2023 full-year financial results on Thursday, March 28, 2024. Inventiva's 2023 full-year financial results will be published on Wednesday, March 27, 2024 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, C
LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.Statistical significance was also achieved on several markers of liver injury, markers of glucose and lipid metabolism, as well as hepatic steatosis.Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.Treatment with lanifibranor alone and in combination with empagliflozin decreased the ratio of visceral abdominal fat
Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, and other diseases with significant unmet medical needs, will hold an investor conference on Tuesday, March 19, to share the results of the LEGEND Phase II trial, a placebo-controlled, study evaluating lanifibranor alone and in combination with the SGLT2 inhibitor empagliflozin in patients with MASH/NASH and type 2 diabetes (T2D). Conference Call / Webcast Details The C
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million1, and long-term deposit at €9.3 million2, as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivelRevenues amounted to €1.9 million for the first half of 2023In August 2023, Inventiva received a financing of approximately €35.7 million from new and existing investors consisting of €30.6 million from a capital increase and €5.1 million issuance of royalty certificatesIn September 2023, Inventiva announced an exclusive licensing agreement with Hepalys Pharma, Inc., to develop and commercialize lanifibranor for the treatment of NASH and potentially other met
Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced an approximately €35.7 million financing. The financing consists of two transactions: (i) a capital increase reserved to specified categories of investors (the "Capital Increase"), for an amount of €30,587,269 million through the issuance of 9,618,638 newly-issued ordinary shares with a nominal value of €0.01 per share (